These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 12720219

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    Georges GE, Maris M, Sandmaier BM, Malone DG, Feinstein L, Niederweiser D, Shizuru JA, McSweeney PA, Chauncey TR, Agura E, Little MT, Sahebi F, Hegenbart U, Pulsipher MA, Bruno B, Forman S, Woolfrey AE, Radich JP, Blume KG, Storb R.
    Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
    [Abstract] [Full Text] [Related]

  • 3. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
    Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT.
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
    [Abstract] [Full Text] [Related]

  • 6. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE, Uberti JP, Ayash L, Reynolds C, Ferrara JL, Silver SM, Braun T, Yanik G, Hutchinson R, Ratanatharathorn V.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [Abstract] [Full Text] [Related]

  • 7. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2001 Mar; 7(11):604-12. PubMed ID: 11760148
    [Abstract] [Full Text] [Related]

  • 8. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
    Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, Storb R.
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [Abstract] [Full Text] [Related]

  • 10. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Feinstein L, Sandmaier B, Maloney D, McSweeney PA, Maris M, Flowers C, Radich J, Little MT, Nash RA, Chauncey T, Woolfrey A, Georges G, Kiem HP, Zaucha JM, Blume KG, Shizuru J, Niederwieser D, Storb R.
    Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
    [Abstract] [Full Text] [Related]

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 12. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
    Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM.
    Leukemia; 2005 Jun; 19(6):990-7. PubMed ID: 15800667
    [Abstract] [Full Text] [Related]

  • 13. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
    Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF.
    Blood; 2003 Feb 15; 101(4):1620-9. PubMed ID: 12393457
    [Abstract] [Full Text] [Related]

  • 14. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
    Piñana JL, Valcárcel D, Martino R, Barba P, Moreno E, Sureda A, Vega M, Delgado J, Briones J, Brunet S, Sierra J.
    Biol Blood Marrow Transplant; 2009 Jan 15; 15(1):21-9. PubMed ID: 19135939
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
    Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R.
    JAMA; 2011 Nov 02; 306(17):1874-83. PubMed ID: 22045765
    [Abstract] [Full Text] [Related]

  • 18. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
    Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S.
    Blood; 2002 Feb 01; 99(3):1071-8. PubMed ID: 11807015
    [Abstract] [Full Text] [Related]

  • 19. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.
    Blood Cells Mol Dis; 2008 Feb 01; 40(1):13-9. PubMed ID: 17869547
    [Abstract] [Full Text] [Related]

  • 20. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, Leppert MF, Storb R, Sandmaier BM.
    Clin Cancer Res; 2004 Dec 01; 10(23):7799-811. PubMed ID: 15585611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.